Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Osivax

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OVX836

            Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: European Innovation Council

            Deal Size: $34.0 million Upfront Cash: Undisclosed

            Deal Type: Funding July 08, 2020

            Details:

            The grant willsupport the completion of the Company’s Phase 2a immunogenicity clinical trial for OVX836, its lead universal flu vaccine candidate and the early discovery phase for its universal coronavirus vaccine program.